+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05702853

Phase 1b Study of Metabolically Enhanced CD19 CAR T-Cell Therapy with CD34 Selection for Adults with Relapsed or Refractory CD19 B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Led by Medical University of South Carolina · Updated on 2026-03-27

27

Participants Needed

1

Research Sites

7 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new metabolically programmed CD19 CAR T-cell therapy with a CD34 selection marker in adults with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma NHL or chronic lymphocytic leukemia CLLsmall lymphocytic lymphoma SLL. This study aims to improve safety, reduce relapse, and enhance the persistence and anti-tumor activity of CAR T-cells by creating a purified, high-quality product using metabolic programming and CD34 selection. The trial is a phase 1b, open-label, nonrandomized study conducted at a single center. Participants receive a dose-escalation of the CD19-CD34t metabolically programmed CAR T-cells infused intravenously in three dose levels ranging from 1 x 106 to 2 x 106 transduced T cells per kg of body weight. Before CAR T-cell infusion, patients undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine administered intravenously on days -5, -4, and -3. The infusion of CAR T-cells is done over 30 minutes or less using nonfiltered tubing to prevent cell clumping. The study will assess safety, dose limits, and optimal dosing over 12 months and up to 24 months for longer-term outcomes. During the study, participants will be closely monitored through clinical evaluations, imaging scans such as PET-CT or CT to measure disease, laboratory tests, and assessments of side effects including cytokine release syndrome and neurotoxicity. The primary outcomes include determining the maximum tolerated and recommended doses, as well as safety events up to 24 months. Secondary measures include response rates, survival, and duration of response. Participants must have adequate caregiver support and will be followed regularly to assess treatment effects and side effects throughout the study period, which may last up to two years.

CONDITIONS

Brief Title

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Research Team

H

HCC Clinical Trials Office

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here